查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493358

美國自體免疫疾病診斷市場規模、佔有率、趨勢分析報告：按類型、測試類型、最終用途、細分市場預測，2024-2030 年

U.S. Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Test Type, By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

美國自體免疫疾病診斷市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國自體免疫疾病診斷市場規模預計將達到30.1億美元，2024年至2030年複合年成長率為5.2%。

自體免疫疾病盛行率的上升以及診斷工具和技術的不斷進步正在顯著推動市場的成長。

醫療保健專業人員和患者對自體免疫疾病的認知不斷提高，導致診斷和篩檢率提高。公共衛生工作、教育宣傳活動和宣傳工作提高了人們對自體免疫疾病徵兆和症狀的認知，促使更多的人尋求早期診斷和治療。針對高風險族群的篩檢計畫也有助於早期發現自體免疫疾病。

全球醫療保健支出的不斷成長以及自體免疫疾病對醫療保健系統帶來的日益沉重的負擔正在推動對先進診斷解決方案的需求。政府和私人組織正在投資醫療基礎設施和研發，以應對自體免疫疾病帶來的挑戰。這項投資將促進診斷技術的創新，並增加自體免疫疾病患者獲得優質診斷服務的機會。

美國自體免疫疾病診斷市場報告亮點

  • 隨著超音波、MRI 和 PET 掃描等先進影像技術的興起，可以對受影響的組織和器官進行詳細可視化，局部自體免疫疾病診斷類型在 2023 年以 66.0% 的佔有率佔據市場主導地位。
  • 抗核抗體測試類型將在 2023 年佔據最大的市場佔有率，並預計在預測期內成長最快。
  • 由於對準確和精確的檢測方法的需求不斷成長，醫院最終用途細分市場將在 2023 年佔據市場主導地位。
  • 2023 年 11 月，Progentec Diagnostics 和 Mayo Clinic Laboratories 宣佈建立策略夥伴關係，將 Progentec 的取得專利的標記血液檢測專利套件商業化，用於自體免疫疾病的早期檢測和治療。該合作夥伴關係旨在改善美國和多個國際市場的患者和臨床醫生的可及性。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國自體免疫疾病診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國自體免疫疾病診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國自體免疫疾病診斷市場：類型估計與趨勢分析

  • 2023 年和 2030 年按類型分類的市場佔有率
  • 細分儀表板
  • 美國自體免疫疾病診斷市場按類型前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 自體免疫疾病診斷
  • 局部自體免疫疾病診斷

第5章美國自體免疫疾病診斷市場：測試類型估計與趨勢分析

  • 2023 年和 2030 年測試類型市場佔有率
  • 細分儀表板
  • 按測試類型分類的美國自體免疫疾病診斷市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 抗核抗體測試
  • 自體抗體測試
  • C反應蛋白
  • 血液常規檢查
  • 尿液檢查
  • 其他

第6章美國自體免疫疾病診斷市場：最終用途估計與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 美國自體免疫疾病診斷市場的最終用途展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院
  • 診斷中心
  • 其他

第7章美國自體免疫疾病診斷市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區分類的市場佔有率佔有率
  • 美國自體免疫疾病診斷市場的區域展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 西
  • 中西部
  • 東北
  • 西南
  • 東南

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • Medtronic
    • Boston Scientific Corporation
    • Johnson &Johnson Service Inc.（Ethicon, Inc.）
    • AngioDynamics
    • Bioventus Inc.（Misonix Inc.）
    • EDAP TMS
    • Chongqing Haifu Medical Technology Co., Ltd
    • Mermaid Medical
    • HealthTronics, Inc.
    • HS Hospital Service SpA
Product Code: GVR-4-68040-285-3

U.S. Autoimmune Disease Diagnostics Market Growth & Trends:

The U.S. autoimmune disease diagnostics market size is anticipated to reach USD 3.01 billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of autoimmune diseases and increasing technological advancements in diagnostic tools and techniques are significantly driving the growth of the market.

Increasing awareness about autoimmune diseases among healthcare professionals and patients has led to a higher rate of diagnosis and screening. Public health initiatives, educational campaigns, and advocacy efforts have raised awareness about the signs and symptoms of autoimmune diseases, prompting individuals to seek early diagnosis and treatment. Screening programs aimed at high-risk populations have also contributed to the early detection of autoimmune conditions.

The increasing healthcare expenditure globally, coupled with the growing burden of autoimmune diseases on healthcare systems, has fueled the demand for advanced diagnostic solutions. The government and private organizations are investing in healthcare infrastructure, research, and development to address the challenges posed by autoimmune diseases. This investment drives innovation in diagnostic technologies and promotes access to quality diagnostic services for patients with autoimmune conditions.

U.S. Autoimmune Disease Diagnostics Market Report Highlights:

  • Localized autoimmune disease diagnostics type dominated the market with a 66.0% share in 2023 owing to the rising advanced imaging techniques, such as ultrasound, MRI, and PET scans, which allow for detailed visualization of affected tissues or organs.
  • The antinuclear antibody test type segment held the largest market share in 2023 and is anticipated to witness the fastest growth over the forecast period.
  • The hospitals end-use segment dominated the market in 2023 owing to the growing need for accurate and precise testing methods.
  • In November 2023, Progentec Diagnostics and Mayo Clinic Laboratories announced a strategic partnership to commercialize Progentec's range of patented biomarker blood tests for the early detection and treatment of autoimmune disorders. The partnership seeks to improve accessibility for patients and clinicians in the United States and a few international markets.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Test Type
    • 1.2.3. End-use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. Test type outlook
    • 2.2.3. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Autoimmune Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Presence of research funding programs
      • 3.2.1.2. Presence of favorable government initiatives
      • 3.2.1.3. Growing patient awareness levels
      • 3.2.1.4. Technological innovation in the form of lab automation
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Slow diagnostic result turnaround times and lack of skilled
  • 3.3. U.S. Autoimmune Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Autoimmune Disease Diagnostics Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. U.S. Autoimmune Disease Diagnostics
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Rheumatoid arthritis
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ankylosing spondylitis diagnostics
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Systemic lupus erythematosus (SLE)
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Localized autoimmune disease diagnostics
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Multiple sclerosis
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Type 1 diabetes
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Hashimoto's Thyroiditis
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.5. Idiopathic thrombocytopenic purpura
      • 4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.6. Others
      • 4.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Test Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Autoimmune Disease Diagnostics Market by Test Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Antinuclear antibody tests
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Autoantibody tests
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. C-reactive Protein (CRP)
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Complete blood count (CBC)
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Urinalysis
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Autoimmune Disease Diagnostics Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Autoimmune Disease Diagnostics Market by End-use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Diagnostic centers
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Autoimmune Disease Diagnostics Market: Region Estimates & Trend Analysis

  • 7.1. Regional Market Share, 2023 & 2030
  • 7.2. U.S. Autoimmune Disease Diagnostics Market by Region Outlook
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.3.1. West
      • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Midwest
      • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Northeast
      • 7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Southwest
      • 7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.5. Southeast
      • 7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Medtronic
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Boston Scientific Corporation
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Johnson & Johnson Service Inc. (Ethicon, Inc.)
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. AngioDynamics
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Bioventus Inc. (Misonix Inc.)
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. EDAP TMS
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Chongqing Haifu Medical Technology Co., Ltd
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Mermaid Medical
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. HealthTronics, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. H.S. Hospital Service S.p.A.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. autoimmune disease diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 U.S. systemic autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 5 U.S. localized autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. autoimmune disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S. autoimmune disease diagnostics market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. Autoimmune disease diagnostics market: market outlook
  • Fig. 9 U.S. Autoimmune disease diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. Autoimmune disease diagnostics market driver impact
  • Fig. 14 U.S. Autoimmune disease diagnostics market restraint impact
  • Fig. 15 U.S. Autoimmune disease diagnostics market: Type movement analysis
  • Fig. 16 U.S. Autoimmune disease diagnostics market: Type outlook and key takeaways
  • Fig. 17 Systemic autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Ankylosing spondylitis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Systemic lupus erythematosus (SLE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Localized autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Multiple sclerosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Type 1 diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Hashimoto's Thyroiditis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Idiopathic thrombocytopenic purpura market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Autoimmune disease diagnostics Market: Treatment movement Analysis
  • Fig. 29 U.S. Autoimmune disease diagnostics market: Treatment outlook and key takeaways
  • Fig. 30 Surgical ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Percutaneous ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Laparoscopic ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Autoimmune disease diagnostics market: application movement analysis
  • Fig. 34 U.S. Autoimmune disease diagnostics market: application outlook and key takeaways
  • Fig. 35 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. Autoimmune disease diagnostics market: regional movement analysis
  • Fig. 42 U.S. Autoimmune disease diagnostics market: regional outlook and key takeaways
  • Fig. 43 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)